modelSorbitol
Extends from Pharmacolibrary.Drugs.ATC.B.B05CX02.
Information
| name: | Sorbitol | |
| ATC code: | B05CX02 | route: | oral |
| compartments: | 1 | |
| dosage: | 10000 | mg |
| volume of distribution: | 0.6 | L |
| clearance: | 80 | mL/min |
| other parameters in model implementation | ||
Sorbitol is a sugar alcohol often used as a sweetener and a medication. Medically, it is used as an osmotic laxative to treat constipation, as a diuretic and irrigating fluid in surgical procedures, and as a component of some intravenous formulations. It is generally regarded as safe, but oral ingestion in high doses can cause gastrointestinal discomfort.
Pharmacokinetics
Pharmacokinetic parameters for sorbitol are not well-documented in the published literature for therapeutic use in humans. Most available data are from preclinical studies, food absorption contexts, or in combination with other substances. No direct human pharmacokinetic compartmental modeling published in peer-reviewed sources was found.
References
Yang, D, et al., & Chen, J (2024). Bioequivalence Study of Epalrestat for Healthy Chinese Subjects. Clinical pharmacology in drug development 13(5) 485–490. DOI:10.1002/cpdd.1347 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37971280
Jain, NK, et al., & Pitchumoni, CS (1987). Sorbitol intolerance in adults. Prevalence and pathogenesis on two continents. Journal of clinical gastroenterology 9(3) 317–319. DOI:10.1097/00004836-198706000-00015 PUBMED:https://pubmed.ncbi.nlm.nih.gov/3611685
Matsui, K, et al., & Yokota, S (2021). Potential pharmacokinetic interaction between orally administered drug and osmotically active excipients in pediatric polypharmacy. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 165 105934–None. DOI:10.1016/j.ejps.2021.105934 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34256099
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)